ReviewThe British journal of radiology2014
The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.
Review in The British journal of radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Mapping Spatiotemporal Heterogeneity in Tumor Profiles by Integrating High-Throughput Imaging and Omics Analysis.ACS omega · 2023Review
- Mapping nucleosome and chromatin architectures: A survey of computational methods.Computational and structural biotechnology journal · 2022Review
- Computed tomography texture-based radiomics analysis in gallbladder cancer: initial experience.Clinical and experimental hepatology · 2021Article
- Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.European radiology · 2021Article
- A preliminary PET radiomics study of brain metastases using a fully automatic segmentation method.BMC bioinformatics · 2020Article
- The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.Nature reviews. Clinical oncology · 2019Review
- Role of Complex Networks for Integrating Medical Images and Radiomic Features of Intracranial Ependymoma Patients in Response to Proton Radiotherapy.Frontiers in medicine · 2019Article
- A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.BMC cancer · 2018Article
- Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis.NeuroImage. Clinical · 2018Article
- Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma.Oncotarget · 2017Article
- Review
- Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increaseEuropean radiology · 2017Article
- Omics approaches to individual variation: modeling networks and the virtual patient.Dialogues in clinical neuroscience · 2016Article
- "RADIOTRANSCRIPTOMICS": A synergy of imaging and transcriptomics in clinical assessment.Quantitative biology (Beijing, China) · 2016Article
- Targeting tumor metastases: Drug delivery mechanisms and technologies.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- C2c: turning cancer into chronic disease.Genome medicine · 2014Article
- Advanced modalities of molecular imaging in precision medicine for musculoskeletal malignancies.World journal of nuclear medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
Tumour heterogeneity has, in recent times, come to play a vital role in how we understand and treat cancers; however, the clinical translation of this has lagged behind advances in research. Although significant advancements in oncological management have been made, personalized care remains an elusive goal. Inter- and intratumour heterogeneity, particularly in the clinical setting, has been difficult to quantify and therefore to treat. The histological quantification of heterogeneity of tumours can be a logistical and clinical challenge. The ability to examine not just the whole tumour but also all the molecular variations of metastatic disease in a patient is obviously difficult with current histological techniques. Advances in imaging techniques and novel applications, alongside our understanding of tumour heterogeneity, have opened up a plethora of non-invasive biomarker potential to examine tumours, their heterogeneity and the clinical translation. This review will focus on how various imaging methods that allow for quantification of metastatic tumour heterogeneity, along with the potential of developing imaging, integrated with other in vitro diagnostic approaches such as genomics and exosome analyses, have the potential role as a non-invasive biomarker for guiding the treatment algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.